Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib - PubMed (original) (raw)
Multicenter Study
. 2006 Jun 1;24(16):2549-56.
doi: 10.1200/JCO.2005.04.9866.
Affiliations
- PMID: 16735708
- DOI: 10.1200/JCO.2005.04.9866
Multicenter Study
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
Masahiko Ando et al. J Clin Oncol. 2006.
Abstract
Purpose: Interstitial lung disease (ILD) is a serious adverse effect of gefitinib, but its prevalence and risk factors remain largely unknown. We examined the prevalence of and risk factors for gefitinib-induced ILD associated with practical use of the drug in Japanese with non-small-cell lung cancer (NSCLC).
Patients and methods: Clinical information was retrospectively assembled for NSCLC patients who started gefitinib treatment at affiliated institutions of the West Japan Thoracic Oncology Group between August 31 and December 31, 2002. Medical records of patients who developed pulmonary infiltrates were reviewed by a central committee of extramural experts for identification of patients with gefitinib-induced ILD. Multivariate logistic or Cox regression analysis was performed to identify independent predictive factors for ILD, antitumor response, and survival.
Results: Seventy cases of and 31 deaths from gefitinib-induced ILD were identified among 1,976 consecutively treated patients at 84 institutions, corresponding to a prevalence of 3.5% and mortality of 1.6%. Gefitinib-induced ILD was significantly associated with male sex, a history of smoking, and coincidence of interstitial pneumonia (odds ratios = 3.10, 4.79, and 2.89, respectively). Predictive factors for response were female sex, no history of smoking, adenocarcinoma histology, metastatic disease, and good performance status (PS), whereas predictive factors for survival were female sex, no history of smoking, adenocarcinoma histology, nonmetastatic disease, good PS, and previous chest surgery.
Conclusion: ILD is a serious adverse effect of gefitinib in the clinical setting that cannot be ignored. However, patient selection based on sex and smoking history can minimize ILD risk and maximize the clinical benefit of gefitinib.
Similar articles
- Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, Kodama T, Saijo N. Takano T, et al. Lung Cancer. 2004 Jul;45(1):93-104. doi: 10.1016/j.lungcan.2004.01.010. Lung Cancer. 2004. PMID: 15196739 Clinical Trial. - Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M; Japan Thoracic Radiology Group; Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T, Nyberg F. Kudoh S, et al. Am J Respir Crit Care Med. 2008 Jun 15;177(12):1348-57. doi: 10.1164/rccm.200710-1501OC. Epub 2008 Mar 12. Am J Respir Crit Care Med. 2008. PMID: 18337594 - Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer.
Kaneda H, Tamura K, Kurata T, Uejima H, Nakagawa K, Fukuoka M. Kaneda H, et al. Lung Cancer. 2004 Nov;46(2):247-54. doi: 10.1016/j.lungcan.2004.04.032. Lung Cancer. 2004. PMID: 15474673 - A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
Park K, Goto K. Park K, et al. Curr Med Res Opin. 2006 Mar;22(3):561-73. doi: 10.1185/030079906X89847. Curr Med Res Opin. 2006. PMID: 16574039 Review. - Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
Shi L, Tang J, Tong L, Liu Z. Shi L, et al. Lung Cancer. 2014 Feb;83(2):231-9. doi: 10.1016/j.lungcan.2013.11.016. Epub 2013 Nov 27. Lung Cancer. 2014. PMID: 24332320 Review.
Cited by
- Optimizing response to gefitinib in the treatment of non-small-cell lung cancer.
Carotenuto P, Roma C, Rachiglio AM, Pasquale R, Franco R, Antinolfi G, Piantedosi F, Illiano A, Botti G, Morabito A, Normanno N, De Luca A. Carotenuto P, et al. Pharmgenomics Pers Med. 2011;4:1-9. doi: 10.2147/PGPM.S6626. Epub 2011 Mar 14. Pharmgenomics Pers Med. 2011. PMID: 23226050 Free PMC article. - Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature.
Zhang X, Li H, Zhu M, Zhang Y. Zhang X, et al. Oncol Lett. 2015 May;9(5):2419-2421. doi: 10.3892/ol.2015.3026. Epub 2015 Mar 11. Oncol Lett. 2015. PMID: 26137083 Free PMC article. - Impairments that influence physical function among survivors of childhood cancer.
Wilson CL, Gawade PL, Ness KK. Wilson CL, et al. Children (Basel). 2015;2(1):1-36. doi: 10.3390/children2010001. Children (Basel). 2015. PMID: 25692094 Free PMC article. - Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia.
Ishiguro Y, Ishiguro H, Miyamoto H. Ishiguro Y, et al. Oncotarget. 2013 Apr;4(4):550-9. doi: 10.18632/oncotarget.939. Oncotarget. 2013. PMID: 23592411 Free PMC article. - Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury.
Yamaoka T, Arata S, Homma M, Homma T, Kusumoto S, Ando K, Manabe R, Kishino Y, Ohba M, Tsurutani J, Takimoto M, Ohmori T, Sagara H. Yamaoka T, et al. Int J Mol Sci. 2019 Aug 17;20(16):4021. doi: 10.3390/ijms20164021. Int J Mol Sci. 2019. PMID: 31426531 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical